Our Novel Platform

Neutralizing the toxic effects of aldehydes:

Starting with a family of small-molecule traps.

Aldeyra has developed a proprietary family of aldehyde traps: new chemical entities that sequester and allow for the degradation of aldehydes. Generally safe and well-tolerated in animal and human testing, these entities exhibit minimal pharmacology and have been shown to bind and trap aldehydes more quickly than aldehydes can bind cellular constituents.

We believe this is the first concerted pharmaceutical effort to lower toxic aldehyde levels. The result is a novel platform of drug candidates with broad therapeutic potential across inflammatory diseases and rare genetic disorders that lead to inborn errors of aldehyde metabolism.

The Challenge

The problem of aldehyde toxicity:

Across an expanse of serious diseases.

Aldehydes are naturally occurring toxins. While nearly every organism has enzymes to catabolize aldehydes, in cases of inflammatory and other types of diseases, aldehydes overwhelm our metabolic systems and lead to significant pathology.

At Aldeyra Therapeutics, our mission is to develop therapies to mitigate the effects of aldehyde toxicity. These therapies represent a novel approach to treat, prevent, or slow the progression of numerous rare and common inflammatory diseases, as well as rare genetic disorders that lead to inborn errors of aldehyde metabolism.

Learn more about the widespread challenge of aldehyde toxicity

Development Status

The current state of our clinical trials:

Potential therapies for Inflammatory Disease and Inborn Errors of Aldehyde Metabolism.

Our lead compound and most advanced product candidate, NS2, has demonstrated clinical efficacy in allergic conjunctivitis and noninfectious anterior uveitis, two ocular inflammatory diseases, and is now in a clinical trial for Sjögren-Larsson Syndrome (SLS), a rare genetic disease that leads to an inborn error of aldehyde metabolism with dermatological and neurological dysfunction.

Allergic Conjunctivitis

Allergic conjunctivitis is a common allergic disease – affecting more than 20% of the population worldwide - that is thought to be mediated in part by pro-inflammatory aldehydes, and is characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in excessive tear production in addition to ocular itching, swelling, and redness. Some patients with allergic conjunctivitis do not respond adequately to anti-histamines (the current standard of care), and are then treated with topical corticosteroids, an anti-inflammatory medication that can lead to cataracts, glaucoma, ulcers on the front of the eye, and increased rates of ocular infections. Thus, there is a need for novel and safe medicines like NS2 that have demonstrated activity in mitigating the symptoms of allergic conjunctivitis.

Noninfectious anterior uveitis

Noninfectious anterior uveitis is a severe, potentially blinding inflammatory eye disease characterized in part by high aldehyde levels that may cause pain, photophobia, redness, loss of vision, and other ocular symptoms. Like allergic conjunctivitis, patients may be treated with topical corticosteroids, but such therapy is toxic and leads to other ocular diseases. By trapping pro-inflammatory aldehydes, NS2 has demonstrated the therapeutic potential to reduce inflammation in noninfectious anterior uveitis.

Sjögren-Larsson Syndrome (SLS)

SLS is caused by genetic mutations in Fatty Aldehyde Dehydrogenase (FALDH) that lead to high fatty aldehyde levels, resulting in severe skin and neurological disease. There are an estimated 1000 patients in the US, but there is no FDA-approved therapy specifically for the disease. By trapping fatty aldehydes and replacing the missing catabolic function of FALDH, NS2 represents a potential therapeutic approach for SLS.

Succinic Semi-Aldehyde Dehydrogenase (SSADH) Deficiency

Succinic Semi-Aldehyde Dehydrogenase (SSADH) Deficiency is a neurological disease caused by genetic mutations that result in elevated levels of succinic semi-aldehyde, a toxic aldehyde that is converted into other metabolites that cause severe neurological dysfunction, including cognitive delay, seizures, and difficulties with strength and movement. Over 400 patients with SSADH deficiency have been identified worldwide, but there is currently no FDA-approved therapy for SSADH Deficiency. By trapping succinic semi-aldehyde, NS2 or other aldehyde traps have the potential to reduce the direct toxicity of succinic semi-aldehyde as well as the formation of neurotoxic metabolites, and represent a novel approach with considerable therapeutic potential in a disease where there remains significant unmet medical need.


Leadership Team

Maximizing our internal capabilities:

From a research, development and strategic viewpoint.

Since 2012, Aldeyra has been guided by a leadership team with exceptional depth and breadth of expertise. This includes first-hand experience with the advancement of promising candidates from lab testing, to early and late-stage clinical trials, to the development of approved drugs. This knowledge, which extends to institutional financing and strategic business development, is augmented by a prominent board of directors with a formidable list of achievements and relevant expertise.

Learn more about our leadership team

Read more about our recent hires here and here.

Read about our career openings here.


We’re looking for a few exceptional people:

Who are ready to make a world of difference.

As our company grows and continues to evolve, we are always looking to enhance our clinical and corporate teams with the talents of gifted and driven individuals. If you’re excited by the prospect of being part of a revolutionary medical technology — and possess the knowledge and initiative to help energize our cause — we would be pleased to hear from you.

Learn more about careers at Aldeyra